Capricor Therapeutics (CAPR)
(Delayed Data from NSDQ)
$5.60 USD
-0.50 (-8.20%)
Updated May 29, 2024 04:00 PM ET
After-Market: $5.57 -0.03 (-0.54%) 5:16 PM ET
4-Sell of 5 4
F Value B Growth B Momentum D VGM
Brokerage Reports
0 items in cart
Capricor Therapeutics, Inc. [CAPR]
Reports for Purchase
Showing records 41 - 60 ( 82 total )
Company: Capricor Therapeutics, Inc.
Industry: Medical - Products
The ''1002 Rollercoaster; HOPE Interim Beats Our Expectations; ALLSTAR Falters; What Now? Target to $2.15
Provider: Rodman & Renshaw, Co.
Company: Capricor Therapeutics, Inc.
Industry: Medical - Products
The ''1002 Rollercoaster; HOPE Interim Beats Our Expectations; ALLSTAR Falters; What Now? Target to $2.15
Provider: H.C. Wainwright & Co., Inc.
Company: Capricor Therapeutics, Inc.
Industry: Medical - Products
2016 Results; HOPE-Duchenne Data in April; Key Janssen Decision by 3Q17; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Capricor Therapeutics, Inc.
Industry: Medical - Products
2016 Results; HOPE-Duchenne Data in April; Key Janssen Decision by 3Q17; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Capricor Therapeutics, Inc.
Industry: Medical - Products
Assuming coverage with a Buy rating and $14 price target.
Provider: Rodman & Renshaw, Co.
Company: Capricor Therapeutics, Inc.
Industry: Medical - Products
Ya Gotta Have Heart; Just Maybe Some Janssen Too; Assuming Coverage at Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Capricor Therapeutics, Inc.
Industry: Medical - Products
We are transferring coverage of CAPR to Director of Research Jeff Martin and placing shares Under Review
Provider: Roth Capital Partners, Inc.
Company: Capricor Therapeutics, Inc.
Industry: Medical - Products
ROTH Healthcare Monthly - Longing for Better Blood at ASH
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Capricor Therapeutics, Inc.
Industry: Medical - Products
Results from HOPE-Duchenne and ALLSTAR in 1Q17; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Capricor Therapeutics, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Capricor Therapeutics, Inc.
Industry: Medical - Products
3Q16 Results; DMD Potential Expanding and Major Catalysts Soon
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Capricor Therapeutics, Inc.
Industry: Medical - Products
Healthcare - Healthcare Monthly Catalyst Tracker; Does The Election Matter to Biotech?
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Capricor Therapeutics, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Capricor Therapeutics, Inc.
Industry: Medical - Products
Cash The Check; Additional NIH Funding to Support Exosome Programs
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Capricor Therapeutics, Inc.
Industry: Medical - Products
Healthcare: Inaugural Healthcare Monthly; Catalysts Galore
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Capricor Therapeutics, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Capricor Therapeutics, Inc.
Industry: Medical - Products
And the Clock Starts...Now; Hand Off to Janssen Decision in Six Months
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Capricor Therapeutics, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Capricor Therapeutics, Inc.
Industry: Medical - Products
Keeping the Eye on the Ball; Department of Defense Is on the Offense
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Capricor Therapeutics, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.